Focused On-demand Library for Small ribosomal subunit protein uS5m

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P82675

UPID:

RT05_HUMAN

Alternative names:

28S ribosomal protein S5, mitochondrial

Alternative UPACC:

P82675; Q4ZFY5; Q96LJ6; Q9BWI4; Q9BYC4

Background:

Small ribosomal subunit protein uS5m, also known as 28S ribosomal protein S5, mitochondrial, plays a crucial role in the mitochondrial ribosome. It is part of the small ribosomal subunit and is involved in the translation of mitochondrial DNA-encoded proteins. The precise function of uS5m within the mitochondrial ribosome suggests its importance in mitochondrial protein synthesis, which is essential for cellular energy production and metabolic processes.

Therapeutic significance:

Understanding the role of Small ribosomal subunit protein uS5m could open doors to potential therapeutic strategies. Its pivotal function in mitochondrial protein synthesis makes it a potential target for addressing diseases linked to mitochondrial dysfunction.